Allogene off-the-shelf CAR-T clears pivotal hurdle, raising hopes for first-line lymphoma use

Allogene's off-the-shelf CAR-T clears a pivotal hurdle — and the hardest question remains open

A therapy derived from donor blood cells, not the patient's own, eliminated cancer in lymphoma patients at more than three times the rate of standard monitoring, according to data released Monday by Allogene Therapeutics — a result that positions the company to pursue the first accelerated approval of an allogeneic CAR-T and test whether a class of cell therapies long limited to specialized academic centers can finally reach community hospitals.

In the interim analysis of the ALPHA3 trial, 58.3% of patients who received cema-cel — an off-the-shelf CAR-T cell therapy — achieved minimal residual disease negativity, meaning no detectable cancer via blood test, compared to 16.7% of patients who were simply observed after initial chemotherapy, according to the company. The 41.6 percentage-point gap cleared Allogene's own internal benchmark of 25% to 30% and, in the words of CEO David Chang, marks "a turning point" for allogeneic cell therapy after years of clinical setbacks and investor skepticism.

The trial enrolled 24 patients with large B-cell lymphoma who had responded to first-line chemotherapy but remained MRD-positive — a signal of high relapse risk — and randomized them to cema-cel or observation, according to Allogene's fourth-quarter results announcement. Twelve patients were assigned to each arm. The interim snapshot measured MRD clearance at a protocol-defined timepoint.

CAR-T therapies reprogram a patient's own immune cells to attack cancer. The six CAR-T drugs approved in the US — from Novartis, Gilead, and Bristol Myers Squibb — all require extracting a patient's blood, engineering their T cells, and returning them weeks later. That personalization makes the treatments powerful but slow, expensive, and logistically complex. Allogene's approach skips the wait: it uses T cells donated by healthy volunteers, edited to avoid immune rejection, and stored ready for infusion.

"We wanted to be a little conservative in how we modeled expectations," Chang said on the company's March earnings call. "But the case we're making is that MRD clearance is a clinically meaningful endpoint that regulators have accepted in other blood cancer settings — and we believe it can accelerate our path to approval."

The result is notable because no approved CAR-T therapy is currently indicated for use immediately after first-line chemotherapy in high-risk patients. If MRD clearance is accepted by regulators as a surrogate for clinical benefit, Allogene could pursue accelerated approval in 2027 for that specific population — creating a market where no competitor currently exists.

"Allogene is the only company with a randomized first-line consolidation study in this setting," said Dr. Zachary Roberts, Allogene's chief medical officer, on the March call. "If MRD clearance holds as a predictor of event-free survival, it could be a very compelling regulatory submission."

The MRD assay underpinning the trial comes from Foresight Diagnostics. ALPHA3 uses the company's CLARITY platform, which applies PhasED-Seq technology to detect circulating tumor DNA at below one part per million — 40 to 100 times more sensitive than competing ctDNA approaches, according to validation studies published in peer-reviewed literature. Without that level of sensitivity, identifying patients with molecular-level residual disease after chemotherapy would not be possible.

The question the trial deliberately does not answer is whether clearing MRD actually keeps patients alive longer. MRD clearance is biologically compelling — in chronic lymphocytic leukemia and multiple myeloma, it has been accepted as a surrogate for approval — but it is not yet validated as a surrogate in large B-cell lymphoma. The April dataset is an interim futility analysis; event-free survival data are not mature. Allogene has pointed to ZUMA-7 and IMvigor011 as consistent with the view that MRD clearance predicts meaningful outcomes, but the company has not committed to a specific survival follow-up timeline, and regulators will make the final call.

The path to this point has been bruising. Allogene was founded in 2018 by former Kite Pharma executives — the team behind Yescarta, which Gilead acquired for $12 billion. But the company's own track record includes a 2021 FDA clinical hold over a chromosomal abnormality detected in a patient's engineered cells, fully removed in January 2022 after investigation confirmed the abnormality was not present in any AlloCAR T product; a 2025 patient death that forced Allogene to discontinue its ALLO-647 immunosuppression antibody and switch to standard fludarabine and cyclophosphamide; and years of doubt about whether off-the-shelf cells could match the efficacy of personalized therapy. The stock traded above $50 at its 2019 IPO and has spent most of the past three years below $5.

The simplified fludarabine-cyclophosphamide regimen made the therapy reproducible enough to test across a wider site network. More than 60 sites in the US and Canada are now enrolling, roughly half community clinics without transplant programs or prior CAR-T experience.

"We think this is deliverable in an infusion clinic," Roberts said. "You don't need transplant infrastructure. That's the long-term bet — that the allogeneic product can go places that autologous CAR-T cannot."

The financial runway is narrow. Allogene ended 2025 with $258.3 million in cash, extending cash runway into the first quarter of 2028, covering what management estimates is needed to complete ALPHA3 enrollment and potentially file for accelerated approval. A December 2025 arbitration cleared the final intellectual property cloud over cema-cel: Allogene retains full US, EU, and UK commercial rights; milestone payments to its licensors are not due until FDA BLA acceptance.

The full interim dataset, including safety results, will be presented on a conference call scheduled for 5:30 a.m. Pacific time on April 13.

Allogene Therapeutics (NASDAQ: ALLO) is based in South San Francisco.